5-Fluorouracil
folinic acid
paclitaxel
Taxol
Bristol-Myers Squibb Company
NJ
effective
salvage therapies
metastatic breast cancer
patients
Paclitaxel
5-fluorouracil
cytotoxicity
MCF-7 cell lines
phase II trial
paclitaxel
day I
folinic acid
5-fluorouracil
days
days
TFL
women
metastatic breast cancer
Analysis
patients
months
follow-up
cycles
TFL
cycles
associated with
grade
neutropenia
hospitalization
cycles
patients
granulocyte colony-stimulating factor
neutropenia
patient
platelet transfusions
Grade 3/4 nonhematologic toxicities
patients
response
complete
responses
partial
response
patients
doxorubicin
exposure
doxorubicin
Plasma
paclitaxel
concentrations
measured
paclitaxel
infusion
patients
TFL
active
regimen
metastatic breast cancer
